National Pension Service Decreases Stock Holdings in Moderna, Inc. $MRNA

Key Points

• The National Pension Service has dramatically reduced its stake in Moderna, Inc., lowering its holdings by 99.8% in the first quarter, owning only 1,212 shares after selling 519,526 shares.
• Moderna's recent earnings report showed a loss of ($2.13) per share, beating analyst expectations of ($2.99), while revenue was recorded at $142 million, exceeding an estimate of $116.26 million.
• Analysts are cautious, with a consensus rating of "Hold" on Moderna's stock and a consensus target price of $43.59, amid varying opinions from multiple research firms.

National Pension Service lowered its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 99.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,212 shares of the company's stock after selling 519,526 shares during the period. National Pension Service's holdings in Moderna were worth $34,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of MRNA. Deutsche Bank AG raised its stake in shares of Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after buying an additional 669,614 shares during the period. Tang Capital Management LLC purchased a new stake in Moderna in the 4th quarter worth about $12,474,000. Bank of New York Mellon Corp raised its stake in Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after acquiring an additional 34,034 shares during the period. Wealthfront Advisers LLC lifted its holdings in Moderna by 143.3% during the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock valued at $879,000 after purchasing an additional 18,268 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd boosted its position in Moderna by 73.5% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 40,772 shares of the company's stock worth $1,156,000 after purchasing an additional 17,268 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

MRNA stock opened at $28.02 on Monday. The firm has a 50 day simple moving average of $29.20 and a two-hundred day simple moving average of $29.35. The stock has a market cap of $10.90 billion, a PE ratio of -3.72 and a beta of 1.83. Moderna, Inc. has a one year low of $23.15 and a one year high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm's revenue was down 41.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.33) EPS. On average, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on MRNA. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Citigroup initiated coverage on shares of Moderna in a report on Friday, August 1st. They set a "neutral" rating and a $40.00 target price on the stock. UBS Group dropped their target price on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Bank of America reduced their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Finally, Cowen began coverage on Moderna in a research note on Sunday, July 13th. They set a "hold" rating on the stock. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $43.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.